COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,223 Articles (22,733 medRxiv, 8,490 bioRxiv)

Most recent first Previous |  Page 442: Articles 4411-4420  | Next

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines in Immunocompromised Individuals: A Systematic Review and Meta-Analysis Using the GRADE Framework
Wang, X., Haeussler, K., Spellman, A., Phillips, L., Ramiller, A., Bausch-Jurken, M., Sharma, P., Krivelyova, A., Vats, S., Van de Velde, N.
10.1101/2023.04.05.23288195 — Posted: 2023-04-06
Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis
Yamamoto, S., Matsuda, K., Maeda, K., Horii, K., Okudera, K., Oshiro, Y., Inamura, N., Nemoto, T., TAKEUCHI, J. S., Li, Y., Konishi, M., Tsuchiya, K., Gatanaga, H., Oka, S., Mizoue, T., Sugiyama, H., Aoyanagi, N., Mitsuya, H., Sugiura, W., Ohmagari, N.
10.1101/2023.04.05.23288162 — Posted: 2023-04-06
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variant
Yamasoba, D., Uriu, K., Plianchaisuk, A., Kosugi, Y., Pan, L., Zahradnik, J., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Ito, J., Sato, K.
10.1101/2023.04.06.535883 — Posted: 2023-04-06
Second-order Citations in Altmetrics: A Case Study Analyzing the Audiences of COVID-19 Research in the News and on Social Media
Alperin, J. P., Fleerackers, A., Riedlinger, M., Haustein, S.
10.1101/2023.04.05.535734 — Posted: 2023-04-06
SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice
Alhammad, Y. M., Parthasarathy, S., Ghimire, R., O'Connor, J. J., Kerr, C. M., Pfannenstiel, J. J., Chanda, D., Miller, C. A., Unckless, R., Zuniga, S., Enjuanes, L., More, S., Channappanavar, R., Fehr, A.
10.1101/2023.04.06.535927 — Posted: 2023-04-06
Lower prevalence of Post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
De Bruijn, S., van Hoek, A. J., Mutubuki, E., Knoop, H., Slootweg, J., Tulen, A. D., Franz, E., van den Wijngaard, C. C., van der Maaden, T.
10.1101/2023.04.05.23288157 — Posted: 2023-04-05
How Interactions During Viral-Viral Coinfection Can Shape Infection Kinetics
Pinky, L., DeAguero, J., Remien, C., Smith, A. M.
10.1101/2023.04.05.535744 — Posted: 2023-04-05
AI-Guided Discovery of Novel SARS-CoV-2 PLpro Inhibitors: Accelerating Antiviral Drug Development in the Fight Against COVID-19
Danter, W. R., Spagnoli, W.
10.1101/2023.04.05.535700 — Posted: 2023-04-05
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection
Lecuyer, D., Nardacci, R., Tannous, D., Gutierrez-Mateyron, E., Deva-Nathan, A., Subra, F., Di Primio, C., Quaranta, P., Petit, V., Richetta, C., Mostefa-Kara, A., Del Nonno, F., Falasca, L., Marlin, R., Maisonnasse, P., Delahousse, J., Pascaud, J., Deprez, E., Naigeon, M., Chaput, N., Paci, A., Saada, V., Ghez, D., Mariette, X., Costa, M., Pistello, M., Allouch, A., Delelis, O., Piacentini, M., Le Grand, R., Perfettini, J.-L.
10.1101/2023.04.05.531513 — Posted: 2023-04-05
SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19
Rong, Z., Mai, H., Kapoor, S., Puelles, V., Czogalla, J., Schaedler, J., Vering, J., Delbridge, C., Steinke, H., Frenzel, H., Schmidt, K., Caliskan, O. S., Wettengel, J. M., Cherif, F., Ali, M., Kolabas, Z. I., Ulukaya, S., Horvath, I., Zhao, S., Krahmer, N., Tahirovic, S., Yildirim, A. O., Huber, T., Ondruschka, B., Bechmann, I., Ebert, G., Protzer, U., Bhatia, H. S., Hellal, F., Erturk, A.
10.1101/2023.04.04.535604 — Posted: 2023-04-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).